Pramipexole 0.25mg is a dopamine agonist used to support the management of Parkinson’s disease and restless legs syndrome. Each pack contains 100 tablets.
Format100 Tablets
Concentration0.25mg
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
Pramipexole is a synthetic non ergot dopamine agonist with high selectivity for D2, D3, and D4 dopamine receptor subtypes and particularly notable for its exceptionally high binding affinity for the D3 receptor subtype relative to D2, a selectivity profile that distinguishes it from older dopamine agonists and has made it a frequently studied reference compound in D3 receptor pharmacology research. FDA approved for Parkinson’s disease and restless legs syndrome, Pramipexole contributes a well documented human clinical literature base spanning neurology, psychiatry, and endocrine research contexts. This formulation delivers 0.25mg per tablet in a 100 count format, a precise low dose presentation suited to the conservative titration based research protocols typical of dopaminergic compound research.
Within the context of CSD’s Estrogen & Prolactin research range, Pramipexole’s most research relevant activity is its D2 receptor agonism at the pituitary lactotroph level. Prolactin secretion from anterior pituitary lactotroph cells is tonically inhibited by dopamine through D2 receptor activation. The same pathway through which endogenous dopamine suppresses prolactin release. Pramipexole’s D2 receptor agonism mimics this inhibitory dopamine signal, producing prolactin suppression through direct pituitary dopaminergic pathway activation. This prolactin lowering mechanism makes Pramipexole a frequently studied compound in research examining hyperprolactinaemia models, prolactin mediated HPG axis suppression, and the dopaminergic regulation of pituitary hormone secretion. A pharmacological application directly relevant to its placement in the Estrogen & Prolactin research category.
Pramipexole’s D3 receptor selectivity adds a second distinct research dimension beyond prolactin regulation. D3 receptors are concentrated in limbic system structures, nucleus accumbens, olfactory tubercle, and ventral striatum. Making D3 selective dopamine agonism a subject of significant research interest in reward pathway modulation, mood regulation, and impulse control research. The combination of D2 mediated prolactin suppression and D3 mediated limbic dopaminergic activity in a single compound makes Pramipexole a versatile research tool spanning neuroendocrinology and neuropsychiatry research contexts simultaneously. Dual research profile that distinguishes it from prolactin suppressing compounds that operate exclusively through hormonal or receptor pathways outside the dopaminergic system.
Every batch of CSD’s Pramipexole is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our Estrogen & Prolactin range covers dopaminergic prolactin regulation alongside SERM and aromatase inhibitor estrogen management research from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside Cabergoline in comparative dopamine agonist and prolactin regulation studies. Browse CSD’s full hormone research range for complete sourcing.
Pramipexole is a prescription non ergot dopamine receptor agonist used to influence dopaminergic signaling within the central nervous system. It acts primarily at D2 family dopamine receptors and has preferential affinity for the D3 receptor subtype. Each tablet contains 0.25mg of pramipexole, with 100 tablets supplied per package.
Immediate release pramipexole is medically indicated for the treatment of Parkinson's disease and moderate to severe primary restless legs syndrome (RLS). Its dopamine receptor activity helps compensate for impaired dopaminergic signaling involved in Parkinson's disease and influences neural pathways associated with the sensory and motor symptoms of RLS.
Pramipexole directly activates dopamine receptors rather than increasing dopamine production itself. It acts at receptors within the D2 family, including D2, D3, and D4 receptors, with particularly strong affinity for D3. This dopaminergic activity allows it to influence motor and sensory pathways affected by altered dopamine signaling.
Pramipexole is eliminated predominantly through the kidneys, with approximately 90% of an administered dose recovered in urine and most of it excreted unchanged. Reduced kidney function can therefore slow clearance and increase drug exposure, which is why prescribing information includes dose adjustments and slower titration for patients with renal impairment.
Pramipexole can cause significant drowsiness and, in some patients, sudden episodes of falling asleep during normal daily activities. Other important risks include orthostatic hypotension, hallucinations or other behavioral changes, and impulse control problems such as compulsive gambling, spending, eating, or increased sexual urges. Pramipexole should be prescribed and monitored by an appropriate healthcare professional.
![RALOXIFENE 60MG X 100 [BONE HEALTH]](https://www.canadasteroiddepot.is/wp-content/uploads/2025/07/RALOXIFENE-60-X-100-300x300.webp)
